Gregg Mamikunian

Author PubWeight™ 11.02^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients.	Pancreas	2008	2.24
2	Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors.	Pancreas	2005	1.27
3	Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.	Pancreas	2006	1.21
4	Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation.	Exp Diabetes Res	2011	1.13
5	A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.	Pancreas	2012	0.96
6	Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.	Pancreas	2010	0.92
7	A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy.	Pancreas	2010	0.86
8	Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms.	Surgery	2012	0.84
9	Validation of neurokinin a assays in the United States and Europe.	Pancreas	2011	0.83
10	A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).	Pancreas	2013	0.80